Intercept Pharmaceuticals
Presence
They are in:
- Holding50%
- Biotechnology50%
Acquisition, funding and merger involving Genextra.
- Advanz Pharma has announced the acquisition of Intercept Pharmaceuticals (posted on May 6 2022).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Intercept Pharmaceuticals
- Jerome Durso, Director, President and Chief Executive Officer
- Nancy Miller-Rich, Director
- Luca Benatti, Director
Create your alert
to follow the executive moves at Intercept Pharmaceuticals.
Biotechnology
Genextra has 2,279 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
Popular contacts in Biotechnology
News
Press releases by Intercept Pharmaceuticals
- Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update | Intercept Pharmaceuticals, Inc.
- Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022 | Intercept Pharmaceuticals, Inc.
- Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) | Intercept Pharmaceuticals, Inc.
- Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S. | Intercept Pharmaceuticals, Inc.
- Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022 | Intercept Pharmaceuticals, Inc.
- Intercept Provides Update on NASH Regulatory Timeline | Intercept Pharmaceuticals, Inc.
- Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC | Intercept Pharmaceuticals, Inc.
- Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis | Intercept Pharmaceuticals, Inc.
- Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update | Intercept Pharmaceuticals, Inc.
- Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments | Intercept Pharmaceuticals, Inc.
- View more press releases Close
Social media about Intercept Pharmaceuticals
- Intercept Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Intercept Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Jerome Durso 
Call Intercept Pharmaceuticals at +1 646...
